コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 22.0% during chemoradiotherapy, 13.4% during maintenance chemotherapy).
2 motherapy (fluorouracil and cisplatin) or no maintenance chemotherapy.
3 rfractionated craniospinal radiotherapy, and maintenance chemotherapy.
4 apy and was continued for up to 12 cycles of maintenance chemotherapy.
5 ll-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.
6 s SCT or intensive consolidation followed by maintenance chemotherapy.
7 cranial radiation only (18 Gy), followed by maintenance chemotherapy.
8 survival and overall survival compared with maintenance chemotherapy.
9 then administered, followed by 1.5 years of maintenance chemotherapy.
10 h blinatumomab followed by 18 months of POMP maintenance chemotherapy.
11 omission of doxorubicin and the addition of maintenance chemotherapy.
12 ps: 186 to stop treatment and 185 to receive maintenance chemotherapy.
13 city was manageable in patients who received maintenance chemotherapy: 136 (75%) of 181 patients had
15 onomic methotrexate-based chemotherapy or no maintenance chemotherapy, a high CDK12 status predicts a
16 hemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves s
19 y fractions); with or without two courses of maintenance chemotherapy (fluorouracil and cisplatin at
20 econd randomisation after initial therapy to maintenance chemotherapy (fluorouracil and cisplatin) or
21 value of alloSCT compared with conventional maintenance chemotherapy for patients in first complete
22 d received a single dose of PCV13: Group 1 - maintenance chemotherapy; Group 2 - end of chemotherapy;
23 nd received a single dose of PCV13: group 1, maintenance chemotherapy; group 2, end of chemotherapy;
24 hemotherapy versus 69.8% (62.2-76.2) without maintenance chemotherapy (hazard ratio [HR] 0.68 [95% CI
26 Study Group (EpSSG) RMS 2005 trial evaluated maintenance chemotherapy in high-risk rhabdomyosarcoma (
27 tuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreate
28 e, 6-mercaptopurine, and methotrexate (POMP) maintenance chemotherapy in this patient population.
29 e baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically
31 Patients on regimen A received 6 months of maintenance chemotherapy (MC) with cyclophosphamide and
32 spitalized within 30 days, most commonly for maintenance chemotherapy, medical device complications,
33 ved ch14.18, 99 received a 12-month low-dose maintenance chemotherapy (MT) instead, and 69 had no add
34 a (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably.
35 r autografting, and the development of novel maintenance chemotherapy or immunotherapy strategies is
37 assigned (1:1) to stop treatment or continue maintenance chemotherapy (six cycles of intravenous vino
38 e baseline CA-125 level before initiation of maintenance chemotherapy strongly predicts the risk of s
39 e survival was 77.6% (95% CI 70.6-83.2) with maintenance chemotherapy versus 69.8% (62.2-76.2) withou
40 l survival was 86.5% (95% CI 80.2-90.9) with maintenance chemotherapy versus 73.7% (65.8-80.1) withou
42 ut daily carboplatin followed by 6 cycles of maintenance chemotherapy with cisplatin, cyclophosphamid
43 stem-cell transplantation (n=149) or to oral maintenance chemotherapy with cyclophosphamide (n=146).
46 MS2005 trial confirm the survival benefit of maintenance chemotherapy with vinorelbine and low-dose c
47 nvestigate whether prolonging treatment with maintenance chemotherapy would improve survival in patie
48 tumors can avoid radiotherapy and prolonged maintenance chemotherapy yet still achieve durable remis